BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
BioCryst Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.50, BioCryst Pharmaceuticals, Inc. trades at 2.0x sales. Over the last twelve months it generated about $967M of revenue and a net loss of $349M. It runs a gross margin of 25.3%, an operating margin of -30.1% and a net margin of -37.4%. It shows return on equity of 94.4%, return on invested capital of -65.4% and a free cash flow yield of 18.2%. On the balance sheet: a debt-to-equity ratio of -2.08 and a current ratio of 2.71. Over the past 52 weeks the share price ranged from $6.23 to $11.22, with a beta of 0.54.
BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.
29 Wall Street analyst ratings cover the stock: 23 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, BioCryst Pharmaceuticals, Inc. (BCRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 37.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 17.2% / 30% · Interest income / Revenue 1.70% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 37.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.2% / 33% · Receivables / Mkt Cap (36m) 5.59% / 49% · Interest income / Revenue 1.70% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 37.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.2% / 33.33% · Receivables / Mkt Cap (24m) 5.59% / 33.33% · Interest income / Revenue 1.70% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 116.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 58.3% / 33.33% · Receivables / Avg Assets (4Q) 21.1% / 33.33% · Interest income / Revenue 1.70% / 5% | Fail |
| FTSE | Debt / Total Assets 138.3% / 33.33% · (Cash+ST Inv) / Total Assets 63.4% / 33.33% · (Cash+Recv) / Total Assets 84.0% / 33.33% · Interest income / Revenue 1.70% / 5% | Fail |
No. As of September 2026, BioCryst Pharmaceuticals, Inc. (BCRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. BioCryst Pharmaceuticals, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 1.70% of each dividend: BioCryst Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.